Persistency, medication prescribing patterns, and medical resource use associated with multiple sclerosis patients receiving oral disease-modifying therapies: a retrospective medical record review-Reference-Cited by-同舟云学术

Persistency, medication prescribing patterns, and medical resource use associated with multiple sclerosis patients receiving oral disease-modifying therapies: a retrospective medical record review

Published:2016-09-29 Issue:1 Volume:16 Page:
ISSN:1471-2377
Container-title:BMC Neurology
language:en
Short-container-title:BMC Neurol

Author:

Nazareth Tara,Friedman Howard S.,Navaratnam Prakash,Herriott Denise A.,Ko John J.,Barr Peri,Sasane Rahul

Funder

Novartis Pharmaceuticals Corporation

Publisher

Springer Science and Business Media LLC

Subject

Neurology (clinical),General Medicine

Link

http://link.springer.com/content/pdf/10.1186/s12883-016-0698-9.pdf

Reference17 articles.

1. Wingerchuk DM, Carter JL. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Mayo Clin Proc. 2014;89(2):225–40. doi: 10.1016/j.mayocp.2013.11.002 .

2. Bergvall N, Petrilla AA, Karkare SU, Lahoz R, Agashivala N, Pradhan A, et al. Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis. J Med Econ. 2014;17(10):696–707. doi: 10.3111/13696998.2014.940422 .

3. Halpern R, Agarwal S, Dembek C, Borton L, Lopez-Bresnahan M. Comparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: a retrospective administrative claims analysis. Patient Prefer Adherence. 2011;5:73–84. doi: 10.2147/PPA.S15702 .

4. Agashivala N, Wu N, Abouzaid S, Wu Y, Kim E, Boulanger L, et al. Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study. BMC Neurol. 2013;13:138. doi: 10.1186/1471-2377-13-138 .

5. Giovannoni G, Southam E, Waubant E. Systematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherence. Mult Scler. 2012;18(7):932–46. doi: 10.1177/1352458511433302 .

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Medication persistence among people with multiple sclerosis in Slovenia treated with dimethyl fumarate;Current Medical Research and Opinion;2023-10-09

2. Medication persistence among persons with multiple sclerosis in Slovenia treated with dimethyl fumarate: a retrospective observational cohort study;2023-06-16

3. Medication persistence among multiple sclerosis patients in Slovenia treated with dimethyl fumarate: a retrospective observational cohort study;2023-02-09

4. Relationship between Patient Preferences, Attitudes to Treatment, Adherence, and Quality of Life in New Users of Teriflunomide;Pharmaceuticals;2022-10-11

5. A novel fatty acid-binding protein 5 and 7 inhibitor ameliorates oligodendrocyte injury in multiple sclerosis mouse models;eBioMedicine;2021-10